Download PDF
Endoscopy 2022; 54(05): 503-508
DOI: 10.1055/a-1550-2503
Innovations and brief communications

Detection of soluble biomarkers of pancreatic cancer in endoscopic ultrasound-guided fine-needle aspiration samples

Régis Souche‡   *
 1   Department of Digestive Surgery and Transplantation, Hôpital Saint Eloi, Centre Hospitalier Universitaire, Université de Montpellier, Montpellier, France
 2   Tumor Microenvironment and Resistance-to-Treatment Laboratory, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier, France
 3   Institut régional du Cancer Montpellier (ICM), Parc Euromédecine, Montpellier, France
 4   Université de Montpellier, Montpellier, France
,
Guillaume Tosato‡   *
 3   Institut régional du Cancer Montpellier (ICM), Parc Euromédecine, Montpellier, France
 4   Université de Montpellier, Montpellier, France
 5   Cancer Bioinformatics and Systems Biology, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France
 6   Centre Hospitalier Universitaire Lapeyronie, Montpellier, France
,
Benjamin Rivière
 7   Department of Pathology, Hôpital Saint Eloi, Centre Hospitalier Universitaire, Université de Montpellier, Montpellier, France
,
Jean-Christophe Valats
 4   Université de Montpellier, Montpellier, France
 8   Department of Hepatogastroenterology, Hôpital Saint Eloi, Centre Hospitalier Universitaire, Université de Montpellier, Montpellier, France
,
Antoine Debourdeau
 4   Université de Montpellier, Montpellier, France
 8   Department of Hepatogastroenterology, Hôpital Saint Eloi, Centre Hospitalier Universitaire, Université de Montpellier, Montpellier, France
,
Nicolas Flori
 3   Institut régional du Cancer Montpellier (ICM), Parc Euromédecine, Montpellier, France
 9   Clinical Nutrition, Gastroenterology and Endoscopy, Univ Montpellier, Institut régional du Cancer Montpellier (ICM), Montpellier, France
,
Didier Pourquier
 2   Tumor Microenvironment and Resistance-to-Treatment Laboratory, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier, France
 3   Institut régional du Cancer Montpellier (ICM), Parc Euromédecine, Montpellier, France
10   Department of Pathology, Institut Régional du Cancer Montpellier (ICM), Montpellier, France
,
Jean-Michel Fabre
 1   Department of Digestive Surgery and Transplantation, Hôpital Saint Eloi, Centre Hospitalier Universitaire, Université de Montpellier, Montpellier, France
 4   Université de Montpellier, Montpellier, France
,
Eric Assenat
 4   Université de Montpellier, Montpellier, France
11   Department of Medical Oncology, Hôpital Saint Eloi, Centre Hospitalier Universitaire, Université de Montpellier, Montpellier, France
,
Jacques Colinge‡   **   **
 3   Institut régional du Cancer Montpellier (ICM), Parc Euromédecine, Montpellier, France
 4   Université de Montpellier, Montpellier, France
 5   Cancer Bioinformatics and Systems Biology, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France
,
Andrei Turtoi  ‡   **
 2   Tumor Microenvironment and Resistance-to-Treatment Laboratory, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier, France
 3   Institut régional du Cancer Montpellier (ICM), Parc Euromédecine, Montpellier, France
 4   Université de Montpellier, Montpellier, France
› Author AffiliationsSupported by: Centre Hospitalier Régional Universitaire de Montpellier http://dx.doi.org/10.13039/501100005261

Trial Registration: ClinicalTrials.gov Registration number (trial ID): NCT03791073 Type of study: Retrospective, Multi-Center
› Further Information
Also available at
    Permissions and Reprints


Referred to by:

Author commentary on Régis Souche et al.Endoscopy 2022; 54(05): v18-v18
DOI: 10.1055/a-1587-9696

Abstract

Background Biomarkers are urgently needed for pancreatic ductal adenocarcinoma (PDAC). Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is the cornerstone for diagnosing PDAC. We developed a method for discovery of PDAC biomarkers using the discarded EUS-FNA liquid.

Methods This retrospective study included 58 patients with suspected pancreatic lesions who underwent EUS-FNA. Protein extracts from EUS-FNA liquid were analyzed by mass spectrometry. Proteomic and clinical data were modeled by supervised statistical learning to identify protein markers and clinical variables that distinguish PDAC.

Results Statistical modeling revealed a protein signature for PDAC screening that achieved high sensitivity and specificity (0.92, 95 % confidence interval [CI] 0.79–0.98, and 0.85, 95 %CI 0.67–0.93, respectively). We also developed a protein signature score (PSS) to guide PDAC diagnosis. In combination with patient age, the PSS achieved 100 % certainty in correctly identifying PDAC patients > 54 years. In addition, 3 /4 inconclusive EUS-FNA biopsies were correctly identified using PSS.

Conclusions EUS-FNA-derived fluid is a rich source of PDAC proteins with biomarker potential. The PSS requires further validation and verification of the feasibility of measuring these proteins in patient sera.

* Co-first authors


** Co-last authors


Supplementary material



Publication History

Received: 28 December 2020

Accepted after revision: 14 June 2021

Article published online:
26 August 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2018; 68: 7-30
    CrossrefPubMedGoogle Scholar
  • 2 Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014; 371: 2140-2141
    PubMedGoogle Scholar
  • 3 Paniccia A, Hosokawa P, Henderson W. et al. Characteristics of 10-year survivors of pancreatic ductal adenocarcinoma. JAMA Surg 2015; 150: 701-710
    CrossrefPubMedGoogle Scholar
  • 4 Conroy T, Hammel P, Hebbar M. et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018; 379: 2395-2406
    CrossrefPubMedGoogle Scholar
  • 5 Neoptolemos JP, Kleeff J, Michl P. et al. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol 2018; 15: 333-348
    CrossrefPubMedGoogle Scholar
  • 6 Korf J, Huinink KD, Posthuma-Trumpie GA. Ultraslow microdialysis and microfiltration for in-line, on-line and off-line monitoring. Trends Biotechnol 2010; 28: 150-158
    CrossrefPubMedGoogle Scholar
  • 7 Tang H, Donnell ET. Application of a model-based recursive partitioning algorithm to predict crash frequency. Accid Anal Prev 2019; 132: 105274
    CrossrefPubMedGoogle Scholar
  • 8 Fogh-Andersen N, Altura BM, Altura BT. et al. Composition of interstitial fluid. Clin Chem 1995; 41: 1522-1525
    CrossrefPubMedGoogle Scholar
  • 9 Gromov P, Gromova I, Olsen CJ. et al. Tumor interstitial fluid – a treasure trove of cancer biomarkers. Biochim Biophys Acta 2013; 1834: 2259-2270
    CrossrefPubMedGoogle Scholar
  • 10 Pavlou MP, Diamandis EP. The cancer cell secretome: a good source for discovering biomarkers?. J Proteomics 2010; 73: 1896-1906
    CrossrefPubMedGoogle Scholar
  • 11 Gronborg M, Kristiansen TZ, Iwahori A. et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 2006; 5: 157-171
    CrossrefPubMedGoogle Scholar
  • 12 Schaaij-Visser TB, de Wit M, Lam SW. et al. The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context. Biochim Biophys Acta 2013; 1834: 2242-2258
    CrossrefPubMedGoogle Scholar
  • 13 Farrah T, Deutsch EW, Omenn GS. et al. A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol Cell Proteomics 2011; DOI: 10.1074/mcp.M110.006353.
    CrossrefPubMedGoogle Scholar
  • 14 Dumartin L, Alrawashdeh W, Trabulo SM. et al. ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation. Oncogene 2017; 36: 3094-3103
    CrossrefPubMedGoogle Scholar
  • 15 Arumugam P, Bhattacharya S, Chin-Aleong J. et al. Expression of polymeric immunoglobulin receptor and stromal activity in pancreatic ductal adenocarcinoma. Pancreatology 2017; 17: 295-302
    CrossrefPubMedGoogle Scholar
  • 16 Tian C, Clauser KR, Ohlund D. et al. Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proc Natl Acad Sci U S A 2019; 116: 19609-19618
    CrossrefPubMedGoogle Scholar